Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX209 Open Label Extension in ASD
NCT01064973Phase 2Terminated
- Sponsor
- Seaside Therapeutics
- Start
- Feb 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arbaclofen in Autism Spectrum Disorder (ASD), sponsored by Seaside Therapeutics. Started Feb 2010; status: terminated.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01064973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064973.